JANX Stock Analysis: Buy, Sell, or Hold?
JANX - Janux Therapeutics, Inc. Common Stock
$13.89
-0.50 (-3.47%)
▼
5d:
-2.01%
30d:
-8.56%
90d:
+5.71%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Distribution
JANX is up 3.6% this week, but smart money is buying puts. Top strike: $12.5 2026-06-18 with 682 OI. Put ratio: 95% View Scanner →
Strength: 6.3/10
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: JANX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: JANX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $13.89, which is considered oversold relative to its 30-day fair value range of $14.25 to $15.28.
Technical Outlook: Technically, JANX is in a uptrend. The price is currently testing key support at $13.77. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.56 (+192.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JANX is in a uptrend. The price is currently testing key support at $13.77. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.56 (+192.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.25 -
$15.28
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 192.0% below Wall St target ($40.56)
Trading Range Analysis
30-Day Trading Range
$14.25 -
$15.28
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.34
(9.6%)
Support & Resistance Levels
Support Level
$13.77
Resistance Level
$14.83
Current Trend
Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.94
Wall Street Target
$40.56
(+192.0%)
Revenue Growth (YoY)
2177.9%
Share & Embed Analysis
Last updated: May 18, 2026 8:20 AM ET
Data refreshes hourly during market hours. Next update: 9:20 AM
Data refreshes hourly during market hours. Next update: 9:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew Hollman Meyer
SELL
1879 shares
2026-01-02
Charles M Winter
SELL
2401 shares
2026-01-02
David Alan Campbell
SELL
8072 shares
2026-01-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 60 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
